Pub. Date : 2018 Jan 23
PMID : 29467959
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. | apatinib | epidermal growth factor receptor | Homo sapiens |
| 2 | Objectives: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. | apatinib | epidermal growth factor receptor | Homo sapiens |
| 3 | Materials and Methods: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. | apatinib | epidermal growth factor receptor | Homo sapiens |
| 4 | Conclusions: Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity. | apatinib | epidermal growth factor receptor | Homo sapiens |